Radiology 2004, 231:491–499.PubMedCrossRef 17. Zielhuis SW, Nijsen JFW, De Roos R, Krijger GC, Van Rijk PP, Hennink WE, Van het Schip AD: Production of GMP-grade radioactive holmium loaded poly(l-lactic acid) microspheres for clinical application. Int J Pharm 2006, 311:69–74.PubMedCrossRef 18. Zielhuis SW, Nijsen JFW, Dorland L, Krijger GC, Van het

Schip AD, Hennink WE: Removal of chloroform from biodegradable therapeutic microspheres by radiolysis. selleck compound Int J Pharm 2006, 315:67–74.PubMedCrossRef 19. Zielhuis SW, Nijsen JFW, Krijger GC, Van het Schip AD, Hennink WE: Holmium-loaded poly(L-lactic acid) microspheres: In vitro degradation study. Biomacromolecules 2006, 7:2217–2223.PubMedCrossRef 20. Nijsen JFW, Rook D, Brandt CJWM, Meijer R, Dullens H, Zonnenberg BA, De Klerk JMH, Van Rijk PP, Hennink WE, Van het Schip AD: Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: a biodistribution study. Eur J Nucl Med 2001, 28:743–749.PubMedCrossRef 21. Nijsen JFW: Radioactive holmium poly(L-lactic acid) microspheres for treatment of hepatic malignancies: efficacy in rabbits. PhD Thesis, Utrecht University, Tthe Netherlands Y-27632 research buy 2001, 109–122. 22. Zielhuis SW, Nijsen JFW, Seppenwoolde JH, Bakker CJG, Krijger GC, Dullens HF, Zonnenberg BA, Van Rijk PP, Hennink WE, Van het Schip AD: Long-term toxicity

of holmium-loaded poly(L-lactic acid) microspheres in rats. Biomaterials 2007, 28:4591–4599.PubMedCrossRef Proton pump inhibitor 23. Vente MAD, Nijsen JFW, De Wit TC, Seppenwoolde JH, Krijger GC, Seevinck PR, Huisman A, Zonnenberg BA, Van den Ingh TSGAM, Van het Schip AD: Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(L: -lactic acid) microspheres in healthy pigs. Eur J Nucl Med Mol Imaging 2008, 35:1259–1271.PubMedCrossRef 24. Aaronson NK, Ahmedzai S, Berman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, De Haes JC, et al.: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365–376.PubMedCrossRef

25. Bolch WE, Bouchet LG, Robertson JS, Wessels BW, Siegel JA, Howell RW, Erdi AK, Aydogan B, Costes S, Watson EE, et al.: MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions–radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med 1999, 40:11S-36S.PubMed 26. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, et al.: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176–181.PubMedCrossRef 27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228–247.PubMedCrossRef 28.